Asunto(s)
Modelos Animales de Enfermedad , Disbiosis/inmunología , Microbioma Gastrointestinal/inmunología , Lupus Eritematoso Sistémico/inmunología , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Animales , Congresos como Asunto , Evaluación Preclínica de Medicamentos/métodos , Reposicionamiento de Medicamentos , Disbiosis/microbiología , Regulación de la Expresión Génica/inmunología , Humanos , Lupus Eritematoso Sistémico/tratamiento farmacológico , Lupus Eritematoso Sistémico/genética , Lupus Eritematoso Sistémico/microbiología , Metformina/uso terapéutico , Ratones , RNA-Seq , Análisis de la Célula Individual , Ubiquinona/análogos & derivados , Ubiquinona/uso terapéutico , Comunicación por VideoconferenciaRESUMEN
Systemic lupus erythematosus is a systemic autoimmune disease driven by a complex combination of genetic, environmental, and other immunoregulatory factors. The development of targeted therapies is complicated by heterogeneous clinical manifestations, varying organ involvement, and toxicity. Despite advances in understanding the mechanisms contributing to SLE, only one biologic drug, belimumab, is FDA-approved. The identification and development of potential therapies have largely been driven by studies in lupus animal models. Therefore, direct comparison of both the therapeutic and immunological findings in human and murine SLE studies is critical and can reveal important insights into indeed how useful and relevant are murine studies in SLE drug development. Studies involving belimumab, mycophenolate mofetil, abatacept, rituximab, and anti-interferon strategies generally demonstrated analogous findings in the attenuation of SLE manifestations and modulation of select immune cell populations in human and murine SLE. While further basic and translational studies are needed to identify SLE patient subsets likely to respond to particular therapeutic modalities and in dissecting complex mechanisms, we believe that despite some inherent weaknesses SLE mouse models will continue to be integral in developing targeted SLE therapies.